Literature DB >> 22018552

Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer.

Yuji Maehata1, Shotaro Nakamura, Kiyoshi Fujisawa, Motohiro Esaki, Tomohiko Moriyama, Kouichi Asano, Yuta Fuyuno, Kan Yamaguchi, Issei Egashira, Hyonji Kim, Motonobu Kanda, Minako Hirahashi, Takayuki Matsumoto.   

Abstract

BACKGROUND: A prospective, randomized trial proved that Helicobacter pylori eradication significantly reduces the incidence of metachronous gastric cancer during a 3-year follow-up.
OBJECTIVE: To investigate the long-term effect of H pylori eradication on the incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer.
DESIGN: Retrospective, multicenter study.
SETTING: Kyushu University Hospital and 6 other hospitals in Fukuoka Prefecture, Japan. PATIENTS AND
INTERVENTIONS: Follow-up data for 268 H pylori-positive patients who had undergone endoscopic resection of early gastric cancer were retrospectively investigated. A total of 177 patients underwent successful H pylori eradication (eradicated group), whereas 91 had persistent H pylori infection (persistent group). MAIN OUTCOME MEASUREMENTS: The incidence of metachronous gastric cancer was compared in these 2 groups.
RESULTS: When the follow-up period was censored at 5 years, the incidence rate in the eradicated group was lower than that observed in the persistent group (P = .007). During the overall follow-up period ranging from 1.1 to 11.1 years (median 3.0 years), metachronous gastric cancer developed in 13 patients (14.3%) in the persistent group and in 15 patients (8.5%) in the eradicated group (P = .262, log-rank test). Based on a multivariate logistic regression analysis, baseline severe mucosal atrophy and a follow-up of more than 5 years were found to be independent risk factors for the development of metachronous gastric cancer. LIMITATIONS: Retrospective study.
CONCLUSIONS: H pylori eradication does not reduce the incidence of metachronous gastric cancer. H pylori eradication should be performed before the progression of gastric mucosal atrophy.
Copyright © 2012 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22018552     DOI: 10.1016/j.gie.2011.08.030

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  72 in total

1.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis.

Authors:  Mitsushige Sugimoto; Masaki Murata; Yoshio Yamaoka
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

Review 3.  Helicobacter pylori in gastric malignancies.

Authors:  Abhishek Bhandari; Sheila E Crowe
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 4.  Endoscopic surveillance strategy after endoscopic resection for early gastric cancer.

Authors:  Tsutomu Nishida; Masahiko Tsujii; Motohiko Kato; Yoshito Hayashi; Tomofumi Akasaka; Hideki Iijima; Tetsuo Takehara
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

Review 5.  Updated evidence on endoscopic resection of early gastric cancer from Japan.

Authors:  Mitsuhiro Fujishiro; Shuntaro Yoshida; Rie Matsuda; Akiko Narita; Hiroharu Yamashita; Yasuyuki Seto
Journal:  Gastric Cancer       Date:  2016-10-04       Impact factor: 7.370

6.  CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.

Authors:  Ying-Xia Zheng; Ming Yang; Ting-Ting Rong; Xiang-Liang Yuan; Yan-Hui Ma; Zhi-Hao Wang; Li-Song Shen; Long Cui
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 7.  Efficacy of Helicobacter pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection for early gastric cancer.

Authors:  Jae Young Jang; Hoon Jai Chun
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Advances in gastric cancer prevention.

Authors:  Antonio Giordano; Letizia Cito
Journal:  World J Clin Oncol       Date:  2012-09-10

Review 9.  Helicobacter pylori: friend or foe?

Authors:  Stephen David Howard Malnick; Ehud Melzer; Malka Attali; Gabriel Duek; Jacob Yahav
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

10.  Role of vacuolating cytotoxin VacA and cytotoxin-associated antigen CagA of Helicobacter pylori in the progression of gastric cancer.

Authors:  Mi-Ran Ki; Meeyul Hwang; Ah-Young Kim; Eun-Mi Lee; Eun-Joo Lee; Myeong-Mi Lee; Soo-Eun Sung; Sang-Hyeob Kim; Hye Seung Lee; Kyu-Shik Jeong
Journal:  Mol Cell Biochem       Date:  2014-07-20       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.